T1	Qualitative_Concept 7 11	last
T2	Quantitative_Concept 22 28	number
T3	Pharmacologic_Substance 32 37	drugs
T4	Activity 43 52	withdrawn
T5	Functional_Concept 53 59	due to
T6	Functional_Concept 60 65	cases
T7	Functional_Concept 75 82	leading
T8	Qualitative_Concept 83 85	to
T9	Research_Activity 96 114	assessment of drug
T10	Clinical_Attribute 115 128	QT interval .
T11	Pharmacologic_Substance 143 154	hydroxyzine
T12	Laboratory_or_Test_Result 159 186	identified as the only drug
T13	Quantitative_Concept 177 181	only
T14	Finding 187 191	able
T15	Qualitative_Concept 192 194	to
T16	Functional_Concept 195 201	induce
T17	Finding 202 227	QTc interval prolongation
T18	Patient_or_Disabled_Group 235 243	patients
T19	Functional_Concept 244 250	active
T20	Pharmacologic_Substance 251 263	medication .
T21	Injury_or_Poisoning 277 297	hydroxyzine overdose
T22	Therapeutic_or_Preventive_Procedure 302 310	detected
T23	Idea_or_Concept 311 319	probably
T24	Functional_Concept 320 326	due to
T25	Disease_or_Syndrome 372 388	liver impairment
T26	Pharmacologic_Substance 415 425	Cetirizine
T27	Pharmacologic_Substance 433 445	hydroxyzines
T28	Qualitative_Concept 446 451	major
T29	Functional_Concept 452 458	active
T30	Biologically_Active_Substance 459 471	metabolite ;
T31	Body_Substance 492 497	blood
T32	Classification 498 503	level
T33	Quantitative_Concept 504 510	dosage
T34	Functional_Concept 515 518	not
T35	Functional_Concept 519 530	performed .
T36	Finding 547 558	combination
T37	Injury_or_Poisoning 562 582	hydroxyzine overdose
T38	Population_Group 587 596	transient
T39	Pathologic_Function 597 610	renal failure
T40	Pharmacologic_Substance 622 626	lead
T41	Qualitative_Concept 627 629	to
T42	Pharmacologic_Substance 630 640	cetirizine
T43	Finding 641 655	accumulation .
T44	Pharmacologic_Substance 666 676	cetirizine
T45	Qualitative_Concept 683 685	to
T46	Clinical_Attribute 758 764	dose .
T47	Quantitative_Concept 772 776	only
T48	Quantitative_Concept 777 780	one
T49	Occupational_Activity 781 790	published
T50	Qualitative_Concept 791 799	clinical
T51	Functional_Concept 800 804	case
T52	Pharmacologic_Substance 808 827	hydroxyzine-induced
T53	Finding 828 845	QT prolongation .
T54	Functional_Concept 851 855	case
T55	Temporal_Concept 866 875	recurrent
T56	Amphibian 876 883	syncope
T57	Pharmacologic_Substance 891 902	hydroxyzine
T58	Research_Activity 903 912	treatment
T59	Qualitative_Concept 916 921	usual
T60	Quantitative_Concept 922 930	posology
T61	Temporal_Concept 936 947	34-year-old
T62	Population_Group 948 953	woman
T63	Idea_or_Concept 954 964	presenting
T64	Gene_or_Genome 967 971	hERG
T65	Genetic_Function 972 982	mutation .
T66	Gene_or_Genome 983 987	hERG
T67	Gene_or_Genome 988 992	gene
T68	Occupational_Activity 993 998	codes
T69	Amino_Acid__Peptide__or_Protein 1007 1014	subunit
T70	Amino_Acid__Peptide__or_Protein 1020 1037	potassium channel
T71	Amino_Acid__Peptide__or_Protein 1044 1045	I
T72	Geographic_Area 1046 1048	Kr
T73	Organ_or_Tissue_Function 1073 1101	ventricular repolarization .
T74	Animal 1126 1131	shown
T75	Pharmacologic_Substance 1137 1148	hydroxyzine
T76	Mental_or_Behavioral_Dysfunction 1175 1183	blocking
T77	Gene_or_Genome 1184 1188	hERG
T78	Spatial_Concept 1189 1197	channels
T79	Cell_Function 1223 1239	action potential
T80	Functional_Concept 1256 1264	inducing
T81	Quantitative_Concept 1278 1284	French
T82	Research_Activity 1285 1302	pharmacovigilance
T83	Quantitative_Concept 1317 1322	found
T84	Functional_Concept 1326 1331	cases
T85	Finding 1335 1350	QT prolongation
T86	Pharmacologic_Substance 1362 1373	hydroxyzine
T87	Idea_or_Concept 1381 1390	suspected
T88	Idea_or_Concept 1391 1405	accountability
T89	Intellectual_Product 1406 1413	assumed
T90	Occupational_Activity 1430 1437	publish
T91	Qualitative_Concept 1447 1452	first
T92	Qualitative_Concept 1453 1461	clinical
T93	Functional_Concept 1462 1466	case
T94	Finding 1492 1507	QT prolongation
T95	Quantitative_Concept 1513 1524	drug dosage
T96	Eukaryote 1525 1531	data .
T97	Social_Behavior 1536 1547	association
T98	Pharmacologic_Substance 1599 1605	others
T99	Qualitative_Concept 1614 1624	well-known
T100	Idea_or_Concept 1629 1634	risks
T101	Functional_Concept 1635 1642	factors
T102	Functional_Concept 1649 1658	including
T103	Finding 1659 1670	hypokalemia
T104	Functional_Concept 1699 1705	induce
T105	Finding 1706 1721	QT prolongation
T106	Finding 1726 1741	lifethreatening
T107	Idea_or_Concept 1752 1759	present
T108	Occupational_Activity 1760 1764	work
T109	Temporal_Concept 1780 1786	recent
T110	Functional_Concept 1787 1795	addition
T111	Pharmacologic_Substance 1799 1810	hydroxyzine
T112	Intellectual_Product 1818 1831	list of drugs
T113	Qualitative_Concept 1837 1848	conditional
T114	Idea_or_Concept 1849 1853	risk
T115	Pharmacologic_Substance 1865 1870	drugs
T116	Qualitative_Concept 1871 1873	to
T117	Patient_or_Disabled_Group 1888 1896	patients
T118	Disease_or_Syndrome 1902 1931	congenital long QT syndrome .
T119	Therapeutic_or_Preventive_Procedure 1940 1947	reminds
T120	Idea_or_Concept 1953 1964	recommended
T121	Clinical_Attribute 1965 1986	hydroxyzines posology
T122	Idea_or_Concept 2011 2015	risk
T123	Finding 2019 2034	QT prolongation
T124	Amphibian 2039 2046	syncope
T125	Quantitative_Concept 2047 2056	increases
T126	Functional_Concept 2073 2077	case
T127	Finding 2084 2094	overdose .
T128	Idea_or_Concept 2105 2116	considering
T129	Quantitative_Concept 2121 2126	large
T130	Functional_Concept 2127 2133	use of
T131	Pathologic_Function 2153 2163	recurrence
T132	Pharmacologic_Substance 2167 2186	hydroxyzine-induced
T133	Finding 2187 2202	QT prolongation
T134	Idea_or_Concept 2206 2214	probably
T135	Idea_or_Concept 2232 2243	Information
T136	Idea_or_Concept 2252 2257	given
T137	Professional_or_Occupational_Group 2261 2272	clinician .
